山东药玻(600529) - 2020 Q3 - 季度财报
SPGSPG(SH:600529)2020-10-19 16:00

Financial Performance - Operating income for the first nine months was CNY 2,311,911,261.66, representing a year-on-year increase of 7.19%[5] - Net profit attributable to shareholders of the listed company was CNY 414,350,151.97, up 21.46% from the same period last year[5] - Basic earnings per share for the period were CNY 0.6964, a 21.45% increase compared to CNY 0.5734 in the previous year[6] - Total operating revenue for Q3 2020 was ¥776,055,900.39, an increase of 7.5% compared to ¥721,553,775.45 in Q3 2019[24] - Net profit for the first three quarters of 2020 reached ¥2,311,911,261.66, compared to ¥2,156,824,384.75 in the same period of 2019, marking an increase of 7.2%[24] - The net profit attributable to shareholders for Q3 2020 was CNY 151.74 million, compared to CNY 123.21 million in Q3 2019, reflecting a year-over-year increase of about 22.9%[26] - The company's total profit for Q3 2020 reached CNY 180.39 million, up from CNY 144.78 million in the same period last year, marking an increase of approximately 24.6%[28] - The operating profit for Q3 2020 was CNY 178.82 million, compared to CNY 140.29 million in Q3 2019, indicating a growth of around 27.4%[28] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 5,431,888,390.25, an increase of 5.06% compared to the end of the previous year[5] - Net assets attributable to shareholders of the listed company amounted to CNY 4,106,090,060.24, reflecting a growth of 6.16% year-on-year[5] - Total current assets as of September 30, 2020, amounted to CNY 3,034,041,677.79, compared to CNY 3,003,247,404.01 at the end of 2019[16] - Total liabilities as of September 30, 2020, were CNY 1,325,798,330.01, compared to CNY 1,302,497,280.42 at the end of 2019[18] - Total assets increased to CNY 5,431,888,390.25 as of September 30, 2020, from CNY 5,170,275,537.49 at the end of 2019[17] - Total liabilities increased to ¥1,237,422,307.24 in Q3 2020 from ¥1,167,885,415.96 in Q3 2019, representing a rise of 5.9%[22] Cash Flow - Cash flow from operating activities for the first nine months was CNY 291,948,256.56, down 25.79% year-on-year[5] - Cash inflow from investment activities was CNY 1,144,702,844.92, a decline from CNY 1,822,501,013.64 in the same period last year, showing a decrease of about 37.2%[32] - The net cash flow from investment activities was negative at CNY -378,846,676.22, compared to CNY -84,807,199.74 in the same period last year[32] - The cash and cash equivalents at the end of Q3 2020 were CNY 694,817,757.72, down from CNY 893,925,975.64 at the end of Q3 2019, representing a decrease of about 22.2%[32] - Cash flow from operating activities for the first three quarters of 2020 was CNY 291,948,256.56, down from CNY 393,383,472.73 in the previous year, reflecting a decrease of approximately 25.8%[30] - The net cash flow from operating activities for the first three quarters of 2020 was ¥298,550,050.34, a decrease from ¥370,574,587.51 in the same period of 2019, reflecting a decline of approximately 19.4%[34] Expenses and Income - Financial expenses increased by 62.07% compared to the same period last year, mainly due to a decrease in exchange gains from RMB appreciation[13] - Other income rose by 45.10% year-on-year, primarily due to an increase in government subsidies[13] - Investment income decreased by 44.72% compared to the previous year, mainly due to reduced returns from bank principal-protected financial products[13] - Research and development expenses for Q3 2020 amounted to ¥40,354,353.85, slightly higher than ¥40,026,880.46 in Q3 2019[24] - The company reported a decrease in sales expenses to ¥53,423,732.62 in Q3 2020 from ¥61,491,112.38 in Q3 2019, a reduction of 13.4%[24] - The company's total operating costs for Q3 2020 were CNY 349.04 million, a decrease from CNY 355.05 million in Q3 2019, representing a reduction of about 1.4%[28] Shareholder Information - The number of shareholders at the end of the reporting period was 137,275, with the largest shareholder holding 21.72% of the shares[8] - The company's retained earnings increased to CNY 2,212,900,432.33 from CNY 1,977,040,604.46 year-on-year[18]